---
company: PETMED EXPRESS INC
ticker: PETS
form: 8-K
filed: 2026-08-13
accession: 0001040130-26-000040
source: https://www.sec.gov/Archives/edgar/data/1040130/000104013026000040/
---

# Petmed Express (PETS) earnings release, August 13, 2026

Petmed Express Inc (PETS) · Form 8-K, Item 2.02 · Filed 2026-08-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1040130/000104013026000040/)

PetMeds® Announces First Quarter Financial Results

Delray Beach, Florida, August 13, 2026, PetMed Express, Inc. dba PetMeds and parent company of PetCareRx (NASDAQ: PETS) today announced its financial results for its first quarter ended June 30, 2026.

Quarterly Highlights

• Net sales demonstrated sequential quarterly stabilization. For the first quarter ended June 30, 2026, net sales were $41.0 million compared to $51.2 million for the prior year period, a decrease of 19.9%, as lower consumer promotional usage was more than offset by a decline in prescription medication sales.

• Net loss for the quarter ended June 30, 2026, was $6.1 million, or $(0.28) per diluted share, compared to a net loss of $34.2 million, or $(1.65) per diluted share, for the prior year period. The decrease in net loss was primarily driven by the absence of the prior-year goodwill and trade name impairment charges and to a lesser extent lower general and administrative expenses and advertising expenses. These favorable factors were partially offset by lower gross profit primarily driven by lower manufacturer rebates as a percentage of sales, partially offset by lower net freight costs per order.

• Adjusted EBITDA¹ was $(3.4) million compared to $(2.7) million in the prior year period.

“Our first quarter results reflect continued progress toward our goal of establishing a direct, clear path back to sustainable profitability," said Leslie Campbell, Chairman and Interim CEO and President of PetMeds. "We are pleased that net sales have stabilized sequentially over the past several quarters, and we continued to make our marketing spend more efficient, acquiring 70,000 new customers while reducing our cost of acquiring a new customer by 15% year-over-year. At the same time, disciplined expense management drove a nearly 14% reduction in general and administrative expenses. We also completed one of the largest milestones in our technology transformation with the enterprise-wide rollout of our new SAP ERP system, further modernizing and strengthening our financial systems and reporting processes. And with our recently announced sale-leaseback transaction, we took an important step toward strengthening our balance sheet and enhancing our financial flexibility to invest in the initiatives with the greatest potential to drive shareholder returns."

Earnings Webcast

A webcast reviewing financial results for the first quarter fiscal year ended June 30, 2026 is available at the “News & Events” section of the Company’s investor relations website at https://investors.petmeds.com/News--Events/events-and-presentations/default.aspx.

About PetMed Express, Inc.

Founded in 1996, PetMeds is a pioneer in the direct-to-consumer pet healthcare sector. As a trusted national online pharmacy, PetMeds is licensed across all 50 states and staffed with expert pharmacists dedicated to supporting pet wellness, pets and pet parents, and the veterinarians who serve them. Through its PETS family of brands and through its PetCareRx subsidiary, the Company offers a comprehensive range of pet health solutions - including top-brand and generic pharmaceuticals, compounded medications, and better-for-your-pet OTC supplements and nutrition. Focused on value, convenience, and care, PetMeds and PetCareRx empower pet parents to help their dogs, cats, and horses live longer, healthier lives. To learn more, visit www.PetMeds.com and www.PetCareRx.com

Forward Looking Statement

This press release may contain “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve a number of risks and uncertainties, including the Company’s ability to meet the objectives included in its business plan. Important factors that could cause results to differ materially from those indicated by such forward-looking statements are set forth in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections in the Company’s Annual Report on Form 10-K to be filed for the year ended March 31, 2026. The Company’s future results may also be impacted by other risk factors listed from time to time in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, the Company's Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and periodic filings on Form 8-K. You should not place undue reliance on these forward-looking statements,¹

Adjusted EBITDA is a non-GAAP financial measure. See “Non-GAAP Financial Measures” for additional information on non-GAAP financial measures and a reconciliation to the most comparable GAAP measures. which apply only as of the date of this press release and should not be relied upon as representing the Company’s views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements, other than as may be required by law. If the Company does update one or more forward-looking statements, no inference should be made that the Company will make additional updates with respect to those or other forward-looking statements.

Investor Contact:

ICR, LLC

Reed Anderson

(646) 277-1260 investor@petmeds.com

## Financial statements

### Income Statement (Three Months Ended June 30, — (In thousands, except for share and per share amounts) (Unaudited))

| | Three Months Ended June 30, – 2026 | 2025 |
|---|---:|---:|
| Net sales | 41,015 | 51,180 |
| Cost of sales | 29,682 | 36,777 |
| Gross profit | 11,333 | 14,403 |
| Operating expenses: | General and administrative | 11,197 | 12,948 |
| Operating expenses: | Advertising | 4,220 | 6,046 |
| Operating expenses: | Depreciation and amortization | 2,148 | 2,283 |
| Operating expenses: | Impairment of goodwill and intangible assets |  | 27,258 |
| Operating expenses: | Total operating expenses | 17,565 | 48,535 |
| Operating expenses: | Loss from operations | -6,232 | -34,132 |
| Other income: | Interest (expense) income, net | -338 | -198 |
| Other income: | Other, net | 438 | 187 |
| Other income: | Total other income (expense) | 100 | -11 |
| Other income: | Loss before provision for income taxes | -6,132 | -34,143 |
| Other income: | Provision for income taxes | 13 | 9 |
| Other income: | Net loss | -6,145 | -34,152 |
| Other income: | Basic and diluted net loss per share | -0.28 | -1.65 |
| Other income: | Basic and diluted weighted-average common shares outstanding | 21,682,381 | 20,755,416 |

### Income Statement (Three Months Ended — PetMed Express, Inc. ($ in thousands, except percentages))

| | Three Months Ended – June 30, 2026 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | Three Months Ended – June 30, 2025 – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | $ Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: | % Change – Consolidated Reconciliation of GAAP Net Loss to Adjusted EBITDA: |
|---|---:|---:|---:|---:|
| Net loss | -6,145 | -34,152 | 28,007 | 82.0% |
| Add (subtract): | Stock-based Compensation | 198 | 591 | -393 | -66.0% |
| Add (subtract): | Income Taxes | 13 | 9 | 4 | 44.0% |
| Add (subtract): | Depreciation and Amortization | 2,148 | 2,283 | -135 | -6.0% |
| Add (subtract): | Interest Expense (Income), Net | 338 | 198 | 140 | 71.0% |
| Add (subtract): | Employee Severance |  | 95 | -95 | n/m |
| Add (subtract): | Professional Fees (1) |  | 1,021 | -1,021 | n/m |
| Add (subtract): | Impairment of goodwill and intangible assets |  | 27,258 | -27,258 | n/m |
| Add (subtract): | Adjusted EBITDA | -3,448 | -2,697 | -751 | 28.0% |

### Balance Sheet ((In thousands, except for share and per share amounts) (Unaudited))

| | June 30, 2026 – (Unaudited) | March 31, 2026 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 13,079 | 21,412 |
| Current assets: | Accounts receivable, less allowance for credit losses of $0 and $25, respectively | 1,706 | 1,908 |
| Current assets: | Inventories, net | 8,468 | 13,608 |
| Current assets: | Prepaid expenses and other current assets | 4,256 | 6,378 |
| Current assets: | Prepaid income taxes | 96 | 258 |
| Current assets: | Total current assets | 27,605 | 43,564 |
| Noncurrent assets: | Property and equipment, net | 25,213 | 26,326 |
| Noncurrent assets: | Intangible and other assets, net | 10,549 | 10,789 |
| Noncurrent assets: | Operating lease right-of-use assets, net | 395 | 512 |
| Noncurrent assets: | Total noncurrent assets | 36,157 | 37,627 |
| Noncurrent assets: | Total assets | 63,762 | 81,191 |
| Current liabilities: | Accounts payable | 12,298 | 20,906 |
| Current liabilities: | Sales tax payable | 20,603 | 22,261 |
| Current liabilities: | Accrued expenses and other current liabilities | 6,654 | 7,665 |
| Current liabilities: | Current operating lease liabilities | 414 | 493 |
| Current liabilities: | Deferred revenue | 629 | 689 |
| Current liabilities: | Income taxes payable |  | 20 |
| Current liabilities: | Total current liabilities | 40,598 | 52,034 |
| Current liabilities: | Deferred tax liabilities, net | 175 | 175 |
| Current liabilities: | Operating lease liabilities, net of current lease liabilities |  | 42 |
| Current liabilities: | Total liabilities | 40,773 | 52,251 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Convertible preferred stock, $0.001 par value, with a liquidation preference of $4 per share, 250,000 shares authorized; 2,500 and 2,500 convertible shares issued and outstanding, respectively | 9 | 9 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Common stock, $.001 par value, 40,000,000 shares authorized; 21,682,381 and 21,385,638 shares issued and outstanding, respectively | 22 | 21 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Additional paid-in capital | 19,840 | 19,647 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Retained earnings | 3,118 | 9,263 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Total shareholders' equity | 22,989 | 28,940 |
| Preferred stock, $0.001 par value, 5,000,000 shares authorized: | Total liabilities and shareholders' equity | 63,762 | 81,191 |

### Cash Flow (Three Months Ended June 30, — (In thousands) (Unaudited) (in thousands))

| | Three Months Ended June 30, – 2026 | Three Months Ended June 30, – 2025 |
|---|---:|---:|
| Cash flows from operating activities: | Net loss | -6,145 | -34,152 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Depreciation and amortization | 2,148 | 2,283 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Impairment of goodwill and intangible assets |  | 27,258 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Share based compensation | 198 | 591 |
| Adjustments to reconcile net loss to net cash used in operating activities: | Bad debt (recovery) expense |  | -6 |
| (Increase) decrease in operating assets and increase (decrease) in operating liabilities: | Accounts receivable | 202 | 718 |
| (Increase) decrease in operating assets and increase (decrease) in operating liabilities: | Inventories | 5,140 | -2,156 |
| (Increase) decrease in operating assets and increase (decrease) in operating liabilities: | Prepaid income taxes | 162 |  |
| (Increase) decrease in operating assets and increase (decrease) in operating liabilities: | Prepaid expenses and other current assets | 2,122 | -1,170 |
